Structure-based Discovery of Cyclin-dependent Protein Kinase Inhibitors

Overview

Journal Essays Biochem

Specialty Biochemistry

Date 2017 Nov 10

PMID 29118092

Citations 20

Authors

Mathew P Martin

Jane A Endicott

Martin E M Noble

Affiliations

Soon will be listed here.

Abstract

The cell fate-determining roles played by members of the cyclin-dependent protein kinase (CDK) family explain why their dysregulation can promote proliferative diseases, and identify them as potential targets for drug discovery in oncology and beyond. After many years of research, the first efficacious CDK inhibitors have now been registered for clinical use in a defined segment of breast cancer. Research is underway to identify inhibitors with appropriate CDK-inhibitory profiles to recapitulate this success in other disease settings. Here, we review the structural data that illustrate the interactions and properties that confer upon inhibitors affinity and/or selectivity toward different CDK family members. We conclude that where CDK inhibitors display selectivity, that selectivity derives from exploiting active site sequence peculiarities and/or from the capacity of the target CDK(s) to access conformations compatible with optimizing inhibitor-target interactions.

Citing Articles

Uncovering potential CDK9 inhibitors from natural compound databases through docking-based virtual screening and MD simulations.

Singh P, Kumar V, Jung T, Lee J, Lee K, Hong J J Mol Model. 2024; 30(8):267.

PMID: 39012568 DOI: 10.1007/s00894-024-06067-z.

Synthetic Approaches and Clinical Application of Representative Small-Molecule Inhibitors of Cyclin-Dependent Kinase for Cancer Therapy.

Wang Y, Jiang S, Zhang S Molecules. 2024; 29(13).

PMID: 38998978 PMC: 11243137. DOI: 10.3390/molecules29133029.

High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design.

Cushing V, Koh A, Feng J, Jurgaityte K, Bondke A, Kroll S Nat Commun. 2024; 15(1):2265.

PMID: 38480681 PMC: 10937634. DOI: 10.1038/s41467-024-46375-9.

Expression of cyclin-dependent kinase 9 is positively correlated with the autophagy level in colon cancer.

Zheng L, Lu J, Kong D World J Gastrointest Oncol. 2024; 16(2):314-330.

PMID: 38425408 PMC: 10900151. DOI: 10.4251/wjgo.v16.i2.314.

Structome: a tool for the rapid assembly of datasets for structural phylogenetics.

Malik A, Langer D, Verma C, Poole A, Allison J Bioinform Adv. 2023; 3(1):vbad134.

PMID: 38046099 PMC: 10692761. DOI: 10.1093/bioadv/vbad134.

References

Dale T, Clarke P, Esdar C, Waalboer D, Adeniji-Popoola O, Ortiz-Ruiz M . A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. Nat Chem Biol. 2015; 11(12):973-980. PMC: 4677459. DOI: 10.1038/nchembio.1952. View

Bettayeb K, Oumata N, Echalier A, Ferandin Y, Endicott J, Galons H . CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene. 2008; 27(44):5797-807. DOI: 10.1038/onc.2008.191. View

Coxon C, Anscombe E, Harnor S, Martin M, Carbain B, Golding B . Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. J Med Chem. 2016; 60(5):1746-1767. PMC: 6111440. DOI: 10.1021/acs.jmedchem.6b01254. View

Malumbres M, Harlow E, Hunt T, Hunter T, Lahti J, Manning G . Cyclin-dependent kinases: a family portrait. Nat Cell Biol. 2009; 11(11):1275-6. PMC: 2914104. DOI: 10.1038/ncb1109-1275. View

Malmstrom J, Viklund J, Slivo C, Costa A, Maudet M, Sandelin C . Synthesis and structure-activity relationship of 4-(1,3-benzothiazol-2-yl)-thiophene-2-sulfonamides as cyclin-dependent kinase 5 (cdk5)/p25 inhibitors. Bioorg Med Chem Lett. 2012; 22(18):5919-23. DOI: 10.1016/j.bmcl.2012.07.068. View

Whittaker S, Mallinger A, Workman P, Clarke P . Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol Ther. 2017; 173:83-105. PMC: 6141011. DOI: 10.1016/j.pharmthera.2017.02.008. View

Bergeron P, Koehler M, Blackwood E, Bowman K, Clark K, Firestein R . Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8. ACS Med Chem Lett. 2016; 7(6):595-600. PMC: 4904263. DOI: 10.1021/acsmedchemlett.6b00044. View

Noble M, Barrett P, Endicott J, Johnson L, McDonnell J, Robertson G . Exploiting structural principles to design cyclin-dependent kinase inhibitors. Biochim Biophys Acta. 2005; 1754(1-2):58-64. DOI: 10.1016/j.bbapap.2005.08.019. View

Copeland R, Pompliano D, Meek T . Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov. 2006; 5(9):730-9. DOI: 10.1038/nrd2082. View

10.

Takaki T, Echalier A, Brown N, Hunt T, Endicott J, Noble M . The structure of CDK4/cyclin D3 has implications for models of CDK activation. Proc Natl Acad Sci U S A. 2009; 106(11):4171-6. PMC: 2657433. DOI: 10.1073/pnas.0809674106. View

11.

Lu H, Schulze-Gahmen U . Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition. J Med Chem. 2006; 49(13):3826-31. DOI: 10.1021/jm0600388. View

12.

Mallinger A, Schiemann K, Rink C, Stieber F, Calderini M, Crumpler S . Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19. J Med Chem. 2016; 59(3):1078-101. PMC: 5362750. DOI: 10.1021/acs.jmedchem.5b01685. View

13.

Malumbres M, Barbacid M . Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9(3):153-66. DOI: 10.1038/nrc2602. View

14.

Deng Y, Shipps Jr G, Zhao L, Siddiqui M, Popovici-Muller J, Curran P . Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor. Bioorg Med Chem Lett. 2013; 24(1):199-203. DOI: 10.1016/j.bmcl.2013.11.041. View

15.

Zhang T, Kwiatkowski N, Olson C, Dixon-Clarke S, Abraham B, Greifenberg A . Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016; 12(10):876-84. PMC: 5033074. DOI: 10.1038/nchembio.2166. View

16.

Potterton L, McNicholas S, Krissinel E, Gruber J, Cowtan K, Emsley P . Developments in the CCP4 molecular-graphics project. Acta Crystallogr D Biol Crystallogr. 2004; 60(Pt 12 Pt 1):2288-94. DOI: 10.1107/S0907444904023716. View

17.

Gray N, Detivaud L, Doerig C, Meijer L . ATP-site directed inhibitors of cyclin-dependent kinases. Curr Med Chem. 1999; 6(9):859-75. View

18.

Schulze-Gahmen U, Kim S . Structural basis for CDK6 activation by a virus-encoded cyclin. Nat Struct Biol. 2002; 9(3):177-81. DOI: 10.1038/nsb756. View

19.

Tarricone C, Dhavan R, Peng J, Areces L, Tsai L, Musacchio A . Structure and regulation of the CDK5-p25(nck5a) complex. Mol Cell. 2001; 8(3):657-69. DOI: 10.1016/s1097-2765(01)00343-4. View

20.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View